{"filing":{"accession_number":"0001534120-26-000048","cik":"0001534120","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"avtx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/avtx-20260806.htm"},"events":[{"id":25807,"run_id":23427,"accession_number":"0001534120-26-000048","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including consolidated balance sheets, statements of operations, cash position ($472.2 million), operating expenses, and net loss ($36.4 million for Q2 2026). The filing includes the full press release as Exhibit 99.1 with detailed financial metrics and business updates, which is the standard format for earnings disclosures.","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26729,"accession_number":"0001534120-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including consolidated balance sheets, statements of operations, cash position ($472.2 million), operating expenses, and net loss ($36.4 million for Q2 2026). The filing includes the full press release as Exhibit 99.1 with detailed financial metrics and business updates, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:35:15.832185+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26729,"accession_number":"0001534120-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including consolidated balance sheets, statements of operations, cash position ($472.2 million), operating expenses, and net loss ($36.4 million for Q2 2026). The filing includes the full press release as Exhibit 99.1 with detailed financial metrics and business updates, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:35:15.832185+00:00","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-08-06"}]}